<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pilocarpine (systemic): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pilocarpine (systemic): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Pilocarpine (systemic): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12290" href="/d/html/12290.html" rel="external">see "Pilocarpine (systemic): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F24521000"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Salagen</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52869938"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP Pilocarpine;</li>
<li>M-Pilocarpine;</li>
<li>Salagen</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F9509745"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Cholinergic Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F9505214"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="601ee7dc-a5e9-4fd0-be6c-83b4e912db8a">Xerostomia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Xerostomia:</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Associated with head and neck cancer:</i> Initial: 5 mg 3 times daily; may titrate dose based on response and tolerability; usual dosage range: 15 to 30 mg/day; maximum: 10 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sjögren disease:</i> 5 mg 4 times daily.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991659"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988964"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh score 5 to 6): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh score 7 to 9): Initial: 5 mg twice daily; adjust dose based on response and tolerability.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh score 10 to 15): Use is not recommended.</p></div>
<div class="block doe drugH1Div" id="F9505215"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F9505074"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Flushing (8% to 13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Diaphoresis (29% to 68%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (6% to 15%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary frequency (9% to 12%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (6% to 12%), chills (3% to 15%), dizziness (5% to 12%), headache (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis (14%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (5%), hypertension (3%), palpitations (1% to 2%), tachycardia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus (1% to 2%), skin rash (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation (1% to 2%), diarrhea (7%), dysgeusia (1% to 2%), dyspepsia (7%), dysphagia (1% to 2%), flatulence (1% to 2%), glossitis (1% to 2%), sialorrhea (3%), stomatitis (1% to 2%), vomiting (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary incontinence (1% to 2%), urinary tract infection (1% to 2%), vaginitis (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Facial edema (1% to 2%), hypersensitivity reaction (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness (1% to 2%), pain (4%), tremor (1% to 2%), voice disorder (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (1% to 2%), myalgia (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Amblyopia (4%), blurred vision (1% to 2%), conjunctivitis (1% to 2%), visual disturbance (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis (1% to 2%), increased cough (1% to 2%), sinusitis (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (1% to 2%), laboratory test abnormality (1% to 2%; including abnormal urine test findings and hematologic abnormality)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest pressure (Aframian 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (Felberg 2022), gastric distress (Farag 2019), gastritis (Aragona 2006), stomach cramps (Chainani-Wu 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Diuresis (Felberg 2022)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (Farag 2019), paresthesia (Brito-Zeron 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Interstitial nephritis (Fujii 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Exacerbation of asthma (Farag 2019)</p></div>
<div class="block coi drugH1Div" id="F9505066"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to pilocarpine or any component of the formulation; uncontrolled asthma; when miosis is undesirable (eg, acute iritis, angle-closure glaucoma)</p></div>
<div class="block war drugH1Div" id="F9505067"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with significant cardiovascular disease; may have difficulty compensating for transient changes in hemodynamics or rhythm induced by pilocarpine.</p>
<p style="text-indent:-2em;margin-left:4em;">• Cholelithiasis: Use with caution in patients with cholelithiasis or biliary tract disease.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with moderate impairment; dosage adjustment recommended; use is not recommended in patients with  severe impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrolithiasis: Use caution in patients with a history of nephrolithiasis; may induce smooth muscle spasms, precipitating renal colic or ureteral reflux in patients with nephrolithiasis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Respiratory disorders: Use with caution in patients with  controlled asthma, chronic bronchitis, or COPD; may increase airway resistance, bronchial smooth muscle tone, and bronchial secretions.</p></div>
<div class="block foc drugH1Div" id="F9505264"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salagen: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salagen: 7.5 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg, 7.5 mg</p></div>
<div class="block geq drugH1Div" id="F9505053"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9505266"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Pilocarpine HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $0.49 - $3.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $2.00 - $4.55</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Salagen Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.21</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">7.5 mg (per each): $2.71</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52869939"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Salagen: 5 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p></div>
<div class="block adm drugH1Div" id="F9505218"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Avoid administering with high-fat meal. Ensure adequate water intake (dehydration may develop with use).</p></div>
<div class="block use drugH1Div" id="F9505054"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Xerostomia: </b> Treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; treatment of symptoms of dry mouth in patients with Sjögren disease.</p></div>
<div class="block mst drugH1Div" id="F9505046"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Salagen may be confused with selegiline</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9505085"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F9505086"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acetylcholinesterase Inhibitors: May enhance the adverse/toxic effect of Cholinergic Agonists. Specifically, cholinergic effects may be enhanced or increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers: May enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cimetropium: Cholinergic Agonists may diminish the anticholinergic effect of Cimetropium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivastigmine: Cholinergic Agonists may enhance the adverse/toxic effect of Rivastigmine. Specifically, cholinergic effects may be enhanced or increased. Rivastigmine may enhance the adverse/toxic effect of Cholinergic Agonists.  Management: Use of rivastigmine with a cholinergic agonist is not recommended unless clinically necessary. If the combination is necessary, monitor for increased cholinergic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sincalide: Drugs that Affect Gallbladder Function may diminish the therapeutic effect of Sincalide.  Management: Consider discontinuing drugs that may affect gallbladder motility prior to the use of sincalide to stimulate gallbladder contraction.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block foi drugH1Div" id="F9505095"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Fat decreases the rate of absorption, maximum concentration and increases the time it takes to reach maximum concentration. Management: Avoid administering with a high-fat meal.</p></div>
<div class="block pri drugH1Div" id="F9887311"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse events have been observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F20617925"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if pilocarpine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends a decision  be made  to discontinue nursing or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>
<div class="block pha drugH1Div" id="F49228945"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Binds to muscarinic (cholinergic) receptors, causing an increase in secretion of exocrine glands (such as salivary and sweat glands) and increase tone of smooth muscle in gastrointestinal and urinary tracts</p></div>
<div class="block phk drugH1Div" id="F9505105"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: 20 minutes; Maximum effect: 1 hour</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 3 to 5 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 0.76 to 1.35 hours; mild to moderate hepatic impairment: 2.1 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: 0.85 to 1.25 hours (increased to 1.47 hours with a high-fat meal)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine</p></div>
<div class="block phksp drugH1Div" id="F51213939"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Clearance decreased ~30% in patients with mild to moderate impairment, resulting in an increase in C<sub>max</sub> and half-life.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: Elderly women had C<sub>max</sub> and AUC approximately twice that of elderly and younger men.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F26530510"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Tensiocap | Wetol</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Pilogen</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Rui er xin</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Balanxart | Carpinelo | Carpix | Pernovin | Picarpin | Pilcard | Piloc | Pilocarpina | Salagen | Salivia | Sitogren</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Pilocarpine Dci | Salagen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Cidren | Prothenol | Saglion | Salagen | Sumario | Xerocarp</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Joegren | Pilomax</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Boryung pilocarpine | Pilocarpine | Pilogen | Salagen</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Caliprene | Eglev</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Pilocarpine | Pilocarpine HCL | Salagen</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Salagen</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Salaflow | Salagen | Salicret</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17241436">
<a name="17241436"></a>Aframian DJ, Helcer M, Livni D, Robinson SD, Markitziu A, Nadler C. Pilocarpine treatment in a mixed cohort of xerostomic patients. <i>Oral Dis</i>. 2007;13(1):88-92. doi:10.1111/j.1601-0825.2006.01252.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/17241436/pubmed" id="17241436" target="_blank">17241436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16424527">
<a name="16424527"></a>Aragona P, Di Pietro R, Spinella R, Mobrici M. Conjunctival epithelium improvement after systemic pilocarpine in patients with Sjogren's syndrome. <i>Br J Ophthalmol</i>. 2006;90(2):166-170. doi:10.1136/bjo.2005.078865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/16424527/pubmed" id="16424527" target="_blank">16424527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31749986">
<a name="31749986"></a>Brito-Zerón P, Retamozo S, Kostov B, et al. Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. <i>RMD Open</i>. 2019;5(2):e001064. doi:10.1136/rmdopen-2019-001064<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/31749986/pubmed" id="31749986" target="_blank">31749986</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16927740">
<a name="16927740"></a>Chainani-Wu N, Gorsky M, Mayer P, Bostrom A, Epstein JB, Silverman S Jr. Assessment of the use of sialogogues in the clinical management of patients with xerostomia. <i>Spec Care Dentist</i>. 2006;26(4):164-170. doi:10.1111/j.1754-4505.2006.tb01719.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/16927740/pubmed" id="16927740" target="_blank">16927740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31520497">
<a name="31520497"></a>Farag AM, Holliday C, Cimmino J, Roomian T, Papas A. Comparing the effectiveness and adverse effects of pilocarpine and cevimeline in patients with hyposalivation. <i>Oral Dis</i>. 2019;25(8):1937-1944. doi:10.1111/odi.13192<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/31520497/pubmed" id="31520497" target="_blank">31520497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34909917">
<a name="34909917"></a>Felberg S, Dantas PEC, Sato EH. Oral pilocarpine for the treatment of dry eye in patients with Sjögren's syndrome. <i>Arq Bras Oftalmol</i>. 2022;85(3):269-276. doi:10.5935/0004-2749.20220069<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/34909917/pubmed" id="34909917" target="_blank">34909917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31077057">
<a name="31077057"></a>Fujii T, Kawasoe K, Nishizawa Y, et al. A suspected case of drug-induced tubulointerstitial nephritis by pilocarpine hydrochloride. <i>CEN Case Rep</i>. 2019;8(4):246-251. doi:10.1007/s13730-019-00401-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/31077057/pubmed" id="31077057" target="_blank">31077057</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1745512">
<a name="1745512"></a>Rhodus NL, Schuh MJ. Effects of Pilocarpine on Salivary Flow in Patients With Sjögren's Syndrome. <i>Oral Surg Oral Med Oral Pathol.</i> 1991;72(5):545-549.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/pilocarpine-systemic-drug-information/abstract-text/1745512/pubmed" id="1745512" target="_blank">1745512</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Salagen (pilocarpine hydrochloride) [prescribing information]. Dublin, Ireland: Amdipharm Ltd; September 2019.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9905 Version 213.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
